Imatinib mesylate induces massive and nonspecific aminoaciduria in cml patients

American Journal of Hematology

Volumn 87, Issue 4, 2012, Pages 437-439

  Ianotto, Jean Christophe ^a   Tempescul, Adrian ^a   Amet, Yolande ^b   Grall, Pauline ^a   Dalbies, Florence ^a   Eveillard, Jean Richard ^a   Guillerm, Gaelle ^a   Berthou, Christian ^a  

^a CHU MORVAN   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; ALANINE; AMINO ACID; ARGININE; ASPARAGINE; CYSTEINE; EPHRIN B1; GLUTAMIC ACID; GLUTAMINE; GLYCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTIDINE; IMATINIB; LEUCINE; LYSINE; MAGNESIUM; METHIONINE; ORNITHINE; PHENYLALANINE; PLATELET DERIVED GROWTH FACTOR; POTASSIUM; SERINE; TAURINE; THREONINE; TYROSINE; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; UREA; VALINE; VASCULOTROPIN;

ADULT; AGED; AMINOACIDURIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FANCONI RENOTUBULAR SYNDROME; FEMALE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY TUBULE ABSORPTION; LETTER; MALE; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; TREATMENT RESPONSE; TUBULAR DYSFUNCTION; UREA BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE REMODELING; FANCONI SYNDROME; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOPHOSPHATEMIA; KIDNEY TUBULES, PROXIMAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RENAL AMINOACIDURIAS;

EID: 84858279632     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23113     Document Type: Letter

References (15)

1. Ra'anani P, Lahav M, Prokocimer M, Poles L. Life threatening hypophosphataemia in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in acute blastic crisis. Postgrad Med J 1992; 68: 283-286.
2. Clark RE, Lee ES. Severe hypophosphataemia during stem cell harvesting in chronic myeloid leukemia. Br J Haematol 1995; 90: 450-452.
3. Berman E, Nicolaides M, Maki RG, Fleisher M. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Eng J Med 2006; 354: 2006-2013.
4. Jonsson S, Olsson B, Ohlsson C, Lorentzon M. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008; 93: 1101-1103.
5. Osorio S, Garcia Noblejas A, Duran A, Steegmann JL. Imatinib mesylate induces hypo-phosphatemia in patients with chronic myeloid leukaemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007; 82: 394-395.
6. Francois H, Coppo P, Hayman JP, Fouqueray B. Partial Fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss. Am J Kidney Dis 2008; 51: 298-301.
7. Vandyke K, Fitter S, Dewar AL, Hughes TP. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010; 115: 766-774.
8. Legros L, Bourcier C, Jacquel A, Mahon FX. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 2004; 104: 495-501.
9. Tenenhouse HS, Murer H. Disorders of renal tubular phosphate transport. J Am Soc Nephrol 2003; 14: 240-247.
10. Van de Poll MC, Soeters PB, Deutz NEP, Fearon KC. Renal metabolism of amino acids: Its role in interorgan amino acid exchange. Am J Clin Nutr 2004; 79: 185-197.
11. Nakagawa T, Sasahara M, Haneda M, Kataoka H. Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury. Am J Pathol 1999; 155: 1689-1699.
12. Gafter-Gvili A, Ram R, Gafter U, Shpilberg O. Renal failure associated with tyrosine kinase inhibitors-Cases report and review of the literature. Leuk Res 2010; 34: 123-127.
13. Tremblay L, Gingras D, Boivin D, Béliveau R. Tyrosine protein kinase activity in renal brush-border membranes. Biochim Biophys Acta 1992; 1108: 183-189.
14. Gibbons J, Egorin MJ, Ramanathan RK, Pingfu F. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: A study by the national cancer institute organ dysfunction working group. J Clin Oncol 2008; 26: 570-576.
15. O'Sullivan S, Lin JM, Watson M, Callon K. The skeletal effects of tyrosine kinase inhibitor nilotinib. Bone 2011; 49: 281-289.